Delivered by: Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers & Associations Based on your experience with the COVID-19 pandemic, what do you believe should be addressed at the international level to better protect against future pandemics?” While we have been part of the largest and most rapid global vaccine rollout in history, we...
Read moreIn a new Note for Guidance, IFPMA and EFPIA provide non-binding advice for their members when considering their activities on social media and digital channels. The document seeks to support and guide pharmaceutical companies and associations and anyone acting on their behalf in always basing their cooperation with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs), Patient...
Read moreIFPMA describes how the R&D-based pharmaceutical industry delivers products with the same quality to all countries around the world, which should facilitate reliance procedures. To facilitate reliance activities, IFPMA has developed a template that provides a transparent overview and description of any differences between the documentation submitted for marketing authorization or post-approval changes in the relying and the reference National Regulatory Agency (NRA).
Read moreOrganized by the Fight the Fakes Alliance during Fight the Fakes Week (5-11 December 2022), this event focused on what medication safety means for patients.
Read moreTo better understand this resulting dichotomy, this white paper answers five key questions, with a focus on applications related to innovation in the life sciences sector and the COVID-19 pandemic.
Read moreThis compendium of facts and figures relating to the biopharmaceutical industry and global health aims to provide a snapshot of the work this industry undertakes today.
Read more13 September 2022, Tel Aviv, Israel – IFPMA and GSCF welcome the opportunity to provide comments and share insights from our Covid-19 Lessons Learned report, , which highlights that swift pathogen surveillance and sharing, an enabling innovation ecosystem, and regulatory agility are among the lessons that must be preserved for future ability to fight against...
Read moreAhead of the Global Fund Seventh Replenishment for 2024-2026, the innovative biopharmaceutical industry reaffirms its longstanding commitment to support the Global Fund mission to defeat HIV, TB, and malaria, and ensure a healthier, safer, more equitable future for all.
Read moreLeveraging the power of collaboration to end HIV, tuberculosis, and malaria.
Read moreViruses don’t stand still. And neither do we. It’s been almost two years since the administration of the first COVID-19 vaccine in December 2020 and as of September 2022, more than two thirds of people worldwide had received at least one COVID-19 vaccine dose.
Read moreIFPMA is delighted to be able to join this SEARO Regional Committee meeting and appreciates the opportunity to make this statement
Read moreIFPMA welcomes the opportunity to comment on the WHO AFRO region’s strategy for health security and emergencies. The innovative biopharmaceutical industry is keen to learn lessons from the COVID-19 pandemic and to work with others to ensure we are much better prepared for the next health emergency. We are not surprised by the assessment from...
Read more